GLP-1 for Prediabetes: Can Semaglutide Reverse It?

If a doctor or lab result recently flagged your blood sugar as higher than normal, you may have received a diagnosis of prediabetes. It does not mean you have type 2 diabetes yet. But it does mean your body is already showing signs that the current trajectory is worth taking seriously.

The good news is that prediabetes is one of the most actionable stages in metabolic health. The choices made now, whether through lifestyle changes, medication, or both, can meaningfully change what happens next. Increasingly, GLP-1 medications like semaglutide and tirzepatide are entering that conversation, and the clinical evidence behind them is more compelling than many people realize.

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here applies to FDA-approved branded products. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication or treatment. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

What Prediabetes Actually Means

Prediabetes is defined by blood glucose levels that are elevated above normal but not yet high enough to meet the diagnostic criteria for type 2 diabetes. The most commonly used markers are:

• Fasting blood glucose: 100 to 125 mg/dL
• A1C: 5.7% to 6.4%
• Two-hour oral glucose tolerance test: 140 to 199 mg/dL

An A1C above 6.4% or fasting glucose above 125 mg/dL on two separate tests crosses into type 2 diabetes territory. Below those thresholds, you are in the prediabetes window.

The underlying issue is insulin resistance. Your pancreas is producing insulin, but your muscles, liver, and fat cells are not responding to it as efficiently as they should. To compensate, your pancreas works harder, producing more insulin to keep glucose levels in check. Over time, if that demand continues to outpace supply, blood sugar climbs.

What makes prediabetes both concerning and actionable is its pace. Without intervention, roughly 15 to 30 percent of people with prediabetes progress to type 2 diabetes within five years, according to the American Diabetes Association. But with the right intervention, that trajectory can reverse. This is where GLP-1 medications have become particularly relevant.

How GLP-1 Medications Work in the Context of Prediabetes

GLP-1 receptor agonists were originally developed to treat type 2 diabetes, and later approved for chronic weight management. Their relevance to prediabetes comes from how they work at a physiological level.

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases in response to food. It signals the pancreas to release insulin, slows digestion to reduce glucose spikes, and acts on the brain to reduce appetite. Medications like semaglutide mimic this hormone, amplifying those effects.

In someone with prediabetes, this produces several useful outcomes at once. First, weight loss, which is among the most powerful drivers of glycemic improvement. Second, direct improvements in insulin sensitivity and beta-cell function, meaning your body becomes better at managing glucose even before you reach a normal weight. Third, reduced post-meal glucose spikes through slowed gastric emptying.

Research published in *Diabetes Care* found that tirzepatide treatment was associated with improvements in both insulin sensitivity and beta-cell function in people with overweight or obesity without type 2 diabetes, and that the beta-cell improvements were only partially explained by weight loss, suggesting a direct medication effect beyond what weight reduction alone would produce [(Mari et al., *Diabetes Care*, 2025; PMID 40694530)](https://pubmed.ncbi.nlm.nih.gov/40694530/).

What the Clinical Evidence Shows

The Landmark Comparison: The Diabetes Prevention Program

Before GLP-1 medications existed, the gold standard for prediabetes intervention was the Diabetes Prevention Program (DPP). This large trial showed that intensive lifestyle modification (diet, exercise, behavioral support) reduced the risk of progressing to type 2 diabetes by 58% compared to placebo. Metformin, the most commonly prescribed medication for prediabetes, reduced risk by 31% [(Knowler et al., *N Engl J Med*, 2002; PMID 11832527)](https://pubmed.ncbi.nlm.nih.gov/11832527/).

These were meaningful results. But the 58% figure required sustained, intensive lifestyle change that many people struggle to maintain outside a clinical trial setting.

The STEP Trials: Prediabetes Subgroup Analysis

The STEP clinical trials tested semaglutide 2.4 mg weekly for weight management in people with overweight or obesity. A dedicated analysis published in *Diabetes Care* examined 1,536 participants who had prediabetes at the start of the trial [(Perreault et al., *Diabetes Care*, 2022; PMID 35724304)](https://pubmed.ncbi.nlm.nih.gov/35724304/).

The results were striking. After 68 weeks:

• In STEP 1, 84.1% of semaglutide participants with baseline prediabetes had returned to normal blood sugar, compared to 47.8% in the placebo group
• In STEP 3, 89.5% of semaglutide participants achieved normoglycemia versus 55.0% in the placebo group
• In STEP 4, the figures were 89.8% versus 70.4%

The semaglutide groups also showed significantly greater improvements in A1C, fasting plasma glucose, and insulin resistance markers. These were not marginal differences.

The SELECT Trial: Cardiovascular Outcomes in People Without Diabetes

The SELECT trial tested semaglutide 2.4 mg in over 17,600 adults with established cardiovascular disease who had overweight or obesity but no type 2 diabetes. Notably, 66.4% of participants had prediabetes at enrollment [(Lincoff et al., *N Engl J Med*, 2023; PMID 37952131)](https://pubmed.ncbi.nlm.nih.gov/37952131/).

The trial found that semaglutide reduced the primary composite endpoint of cardiovascular death, non-fatal heart attack, or non-fatal stroke by 20% compared to placebo (HR 0.80). A prespecified analysis found that this cardiovascular benefit was independent of baseline A1C level, meaning it applied to people with prediabetes, not only to those who were already diabetic.

This matters because prediabetes is not just a blood sugar issue. Elevated glucose, even in the prediabetes range, is associated with increased cardiovascular risk. The SELECT data suggest that GLP-1 treatment may offer cardiovascular protection at this stage.

Semaglutide vs. Tirzepatide for Prediabetes

Both semaglutide and tirzepatide show meaningful glycemic benefits in people with prediabetes, but they work differently.

Semaglutide is a GLP-1 receptor agonist. It activates the GLP-1 pathway. Tirzepatide is a dual agonist, targeting both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. That dual mechanism is associated with somewhat greater average weight loss in head-to-head clinical comparisons.

A 2026 review in *Primary Care Diabetes* synthesized the available evidence for both medications in people with prediabetes and found that tirzepatide reduced the incidence of progression to type 2 diabetes by approximately 90% in the SURMOUNT-1 trial (hazard ratio 0.07), an effect largely explained by substantial weight loss [(Tentolouris et al., *Prim Care Diabetes*, 2026; PMID 41565568)](https://pubmed.ncbi.nlm.nih.gov/41565568/).

For a detailed comparison of these two medications, see our guide to [semaglutide vs. tirzepatide](/resources/semaglutide-vs-tirzepatide-which-glp1-is-right-for-you).

Can GLP-1s Actually Reverse Prediabetes?

The short answer is: yes, in many cases, while you are taking the medication.

The STEP data show that 84 to 90% of people with prediabetes who used semaglutide for 68 weeks returned to normal blood glucose levels. The term for this is "regression to normoglycemia," and it is a documented, measurable outcome, not a marketing claim.

The more nuanced answer involves understanding what "reversal" means in practice. Prediabetes is driven by a combination of insulin resistance and impaired beta-cell function. GLP-1 medications improve both. But these effects are largely dependent on continued treatment. When semaglutide is discontinued, some of the glycemic improvement fades, particularly in people who regain weight.

This does not make the improvement less meaningful. It means GLP-1 medications, when combined with lifestyle changes, can shift the metabolic environment in ways that protect long-term health. For someone who uses this window to build sustainable dietary and exercise habits, the benefits may extend well beyond the period of treatment.

Do You Need a Type 2 Diabetes Diagnosis to Get a GLP-1 Prescription?

No. FDA approval for semaglutide (as Wegovy) and tirzepatide (as Zepbound) covers chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity. Prediabetes qualifies as a comorbidity under current prescribing guidelines.

You do not need a type 2 diabetes diagnosis to be a candidate. Your weight, BMI, and overall metabolic health profile are what most providers will evaluate. Some providers will also consider prescribing GLP-1 medications off-label for prediabetes management at lower BMI thresholds, at their clinical discretion.

For a full overview of who typically qualifies, see our guide to [who qualifies for GLP-1 medications](/resources/who-qualifies-for-glp1-medications).

What to Discuss With Your Provider

If you have prediabetes and are considering a GLP-1 medication, here are the questions worth raising in your next appointment:

• Does my A1C and BMI make me a candidate for semaglutide or tirzepatide?
• What lifestyle changes should I prioritize alongside medication?
• What monitoring schedule makes sense for my blood sugar?
• How do compounded formulations compare to branded options given my situation?
• What is the plan if I need to discontinue the medication at some point?

Your provider will weigh your full history, not just your A1C, when making this decision. Be prepared to discuss your weight history, any past attempts at lifestyle intervention, and your family history of diabetes.

The Bottom Line

A prediabetes diagnosis is not a sentence. It is a signal that the window for meaningful change is open. GLP-1 medications like semaglutide and tirzepatide have produced some of the most clinically significant prediabetes outcomes ever documented, with normoglycemia rates approaching 85 to 90% in controlled trials. Combined with changes in diet and activity, they represent a genuinely powerful option.

Whether or not a GLP-1 medication is right for you depends on your individual health profile. If you have prediabetes and have been told to "watch your diet and come back in six months," it may be worth asking your provider whether there is more you can do now.

Prescriva connects you with licensed providers who can review your health history, discuss your options, and, if appropriate, provide access to compounded semaglutide or tirzepatide. [Start your assessment](/assessment) to see if you may qualify.

---

*This article is for informational purposes only and does not constitute medical advice. Compounded semaglutide and tirzepatide are not FDA-approved. Consult a licensed healthcare provider before making any changes to your treatment plan.*

See Also

• [Semaglutide for Type 2 Diabetes](/resources/semaglutide-for-type-2-diabetes)
• [What Is Compounded Semaglutide?](/resources/compounded-semaglutide-what-it-is)
• [Who Qualifies for GLP-1 Medications?](/resources/who-qualifies-for-glp1-medications)
• [Semaglutide vs. Tirzepatide: Which Is Right for You?](/resources/semaglutide-vs-tirzepatide-which-glp1-is-right-for-you)